Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin –Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study

ConclusionAfter exposure to piperacillin –tazobactam and vancomycin in combination, there was a greater release of AKI biomarkers in patients who develop AKI than with piperacillin–tazobactam or vancomycin monotherapy and the combination is associated with possible increased long-term adverse outcomes.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research